The Atlanta Lung Cancer Symposium (ALCS), now in its twelfth year, is a pioneering educational program addressing current, practical strategies and state-of-the-art approaches for managing lung cancer.
The advent of precision medicine has brought about a sea change in the way lung cancer is diagnosed, managed, and treated. There are multiple FDA-approved and pipeline targeted therapies that are based on genomic biomarkers such as EGFR, ALK, ROS1, and BRAF. More recently, immunotherapy has become accepted broadly as an effective treatment modality for patients with cancer, including NSCLC.
Evolving research and clinical data have the potential to shift the standard of care even further. With these advances come challenges, namely careful consideration of the many factors practitioners face in making the best treatment decision.
The ALCS offers a unique opportunity to gain the most up-to-date information to help optimally diagnose and treat patients with lung cancer. This educational event will incorporate a multidisciplinary perspective utilizing plenary sessions, engaging discussions, and top experts. The symposium will deliver the most current information in the lung cancer field, as well as an opportunity to share experiences and challenges with fellow lung cancer experts.
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
SynAptiv and Phillips Gilmore Oncology Communications, Inc. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians.
Nursing and pharmacy credits are pending.
Describe current monotherapy and combination treatment approaches with
Define biomarkers for immunotherapy and discuss the role of immunotherapy in
patients with driver mutations
Review current treatment approaches for patients with early-stage NSCLC
Identify emerging strategies for targeted therapy
Review developments in the management of advanced stage NSCLC, squamous cell
carcinoma, and small cell lung cancer
Describe the role of chemoradiotherapy and immunotherapy for stage III NSCLC
This activity is supported by grants from AstraZeneca and Bristol-Myers Squibb